YOLFTbeta
Cellectis SA

Cellectis SA

CLLS · NASDAQ · Healthcare / Biotechnology

1.18USD-0.15 (-11.28%)

Price History

Full chart

Market Stats

Previous Close1.33
Open1.16
Day Range1.10 – 1.24
52-Week Range1.25 – 5.48
Volume72.02K
Market Cap144.03M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.63
Dividend Yield0.00%
Beta2.77
50-Day Avg2.78
200-Day Avg3.53

About

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Andre Choulika Ph.D.
  • Employees224
  • Headquarters8, rue de la Croix Jarry, Paris, France, 75013, USA
  • Websitehttps://www.cellectis.com

Leadership

  • Dr. Andre Choulika Ph.D.Co-Founder, CEO & Director · b. 1965
  • Dr. David J. Sourdive Ph.D.Co-Founder, Deputy CEO, Executive VP of CMC & Manufacturing and Director · b. 1967
  • Mr. Arthur StrilCFO & Chief Business Officer · b. 1989
  • Valerie CrosPrincipal Financial Officer & Principal Accounting Officer
  • Mr. Jean Charles Epinat Ph.D.Chief Technological Officer
  • Dr. Philippe Duchateau Ph.D.Chief Scientific Officer · b. 1963
  • Ms. Marie-Bleuenn TerrierGeneral Counsel & Secretary of the Board of Directors · b. 1982
  • Pascalyne WilsonDirector of Communications
  • Ms. Kyung Nam-WortmanExecutive VP & Chief Human Resources Officer · b. 1970
  • Mr. Stephan Reynier M.Sc.Chief Regulatory & Pharmaceutical Compliance Officer · b. 1969

Financials

Income Statement

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.10M14.77M17.32M20.98M20.73M27.81M22.82M26.30M55.04M42.58M25.19M12.73M15.19M73.95M73.95M19.17M755.00K41.51M72.95M
Growth (%)-+260.13%+17.26%+21.14%-1.20%+34.19%-17.97%+15.26%+109.30%-22.63%-40.85%-49.46%+19.32%+386.83%0.00%-74.08%-96.06%+5397.48%+75.76%
Cost of Revenue1.48M1.54M2.33M1.92M3.26M2.03M847.86K3.69M2.71M1.69M2.62M2.74M11.39M36.27M36.27M1.77M7.42M9.18M9.80M
Gross Profit2.62M13.23M14.99M19.06M17.47M25.78M21.97M22.61M52.34M40.90M22.57M9.99M3.80M37.67M37.67M17.40M-6.66M32.32M63.15M
Gross Margin63.99%89.56%86.57%90.84%84.27%92.70%96.28%85.97%95.08%96.04%89.60%78.49%25.00%50.95%50.95%90.76%-882.65%77.88%86.57%
Operating Expense10.41M18.02M28.49M34.31M42.78M51.92M102.59M28.99M82.87M104.86M115.22M115.08M127.35M123.11M123.11M107.06M90.64M91.88M96.23M
Operating Income-7.78M-4.80M-13.50M-15.25M-25.31M-26.14M-80.62M-6.38M-30.53M-63.96M-92.65M-105.09M-123.55M-85.44M-85.44M-89.67M-97.30M-59.55M-33.08M
Operating Margin-189.73%-32.48%-77.92%-72.68%-122.09%-93.98%-353.35%-24.25%-55.46%-150.20%-367.83%-825.47%-813.38%-115.54%-115.54%-467.72%-12887.68%-143.48%-45.34%
EBITDA-5.99M-3.36M-12.25M-12.98M-25.31M-26.14M1.17M370.08K-26.21M-65.32M-108.08M-102.71M-116.68M-75.62M-68.87M-71.23M-92.64M-9.46M-39.85M
EBITDA Margin-146.11%-22.77%-70.74%-61.87%-122.10%-93.98%5.13%1.41%-47.63%-153.38%-429.09%-806.80%-768.12%-102.26%-93.13%-371.56%-12269.80%-22.80%-54.62%
Net Income-4.36M185.15K-5.52M-10.72M-30.90M-29.45M-84.28M24.32K-22.46M-63.92M-99.37M-78.69M-90.69M-72.57M-86.28M-98.69M-101.06M-36.76M-67.59M
Net Income Margin-106.22%1.25%-31.87%-51.11%-149.05%-105.89%-369.38%0.09%-40.81%-150.10%-394.51%-618.12%-597.01%-98.14%-116.68%-514.78%-13385.30%-88.57%-92.66%
R&D---16.37M15.95M25.10M34.44M17.52M57.30M74.56M79.23M76.57M92.04M86.95M86.95M97.50M87.65M90.54M93.52M
R&D as % of Total Revenue---78.04%76.95%90.25%150.95%66.62%104.10%175.10%314.54%601.42%605.94%117.58%117.58%508.59%11608.74%218.13%128.20%
Interest Expense29.16K13.92K8.60K203.48K632.49K1.74M432.80K195.78K22.96K6.31K560.00K46.00K2.61M12.05M5.34M3.79M5.31M7.45M8.11M
Interest Expense % of Total Revenue0.71%0.09%0.05%0.97%3.05%6.24%1.90%0.74%0.04%0.01%2.22%0.36%17.16%16.29%7.22%19.75%702.91%17.96%11.11%

Balance Sheet

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets53.87M60.83M91.34M69.23M131.89M115.11M44.11M167.34M372.88M330.68M332.88M500.84M467.47M469.47M382.08M261.22M334.27M383.54M324.72M
Total Liabilities10.33M14.62M18.12M19.10M94.86M33.42M37.46M94.95M84.67M56.63M46.98M50.57M112.00M160.63M145.60M135.28M249.57M252.51M248.82M
Total Equity43.54M46.21M73.22M50.13M37.02M78.93M6.95M73.92M288.22M274.05M266.79M409.30M315.12M283.80M221.29M117.97M84.69M131.03M75.90M
Cash36.74M39.78M65.33M31.98M54.93M28.84M10.44M136.62M343.56M290.50M296.98M451.89M360.91M241.15M185.64M89.79M136.71M143.25M63.58M
Total Debt--2.62M1.82M69.08M5.67M5.61M4.48M2.17M1.76M34.00K1.35M47.61M106.68M100.87M75.77M85.06M91.46M119.90M
Net Debt-36.74M-39.78M-62.71M-30.16M14.15M-23.17M-4.82M-132.13M-341.38M-288.74M-296.95M-450.54M-313.30M-134.47M-84.77M-14.02M-51.65M-51.79M56.32M

Cash Flow

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-5.62M1.78M-7.05M-21.10M-13.19M-26.11M-25.63M50.74M3.54M-31.09M-52.33M-68.14M-69.14M-80.26M-104.56M-87.44M-24.75M22.10M-40.14M
Investing Cash Flow316.39K-1.12M316.64K-5.69M-29.41M-6.10M-2.08M-1.65M-7.61M-50.50M1.78M35.62M-35.87M-54.34M7.28M-2.76M-15.51M-102.63M-29.58M
Financing Cash Flow34.79M4.05M30.91M-1.18M66.39M4.93M7.50M70.41M217.35M460.64K41.27M236.49M-3.86M27.32M47.52M1.15M82.86M89.80M-16.20M
Capital Expenditure147.26K790.71K713.51K6.66M4.25M5.49M1.91M430.47K4.25M13.34M2.66M4.89M12.96M44.42M18.56M2.44M1.07M2.58M2.37M
Free Cash Flow-5.77M988.39K-7.76M-27.76M-17.44M-31.60M-27.54M50.31M-715.02K-44.42M-54.98M-73.02M-82.10M-124.68M-123.12M-89.89M-25.82M19.52M-42.50M
Dividends Paid-------------00569.00K000
FCF to OCF102.62%55.56%110.12%131.55%132.20%121.01%107.47%99.15%-20.21%142.90%105.08%107.17%118.74%155.35%117.75%102.79%104.34%88.33%105.90%
Dividend Paid to FCF-------------0.00%0.00%-0.63%0.00%0.00%0.00%

Earnings

Report DateJun 9, 2015Sep 9, 2015Nov 16, 2015Mar 16, 2016May 11, 2016Sep 8, 2016Nov 22, 2016Mar 17, 2017May 9, 2017Aug 2, 2017Nov 13, 2017Mar 12, 2018May 7, 2018Aug 1, 2018Nov 13, 2018Mar 11, 2019May 7, 2019Aug 6, 2019Nov 6, 2019Mar 4, 2020May 6, 2020Aug 5, 2020Nov 5, 2020Mar 4, 2021May 6, 2021Aug 5, 2021Nov 4, 2021Mar 3, 2022May 12, 2022Aug 4, 2022Nov 3, 2022Mar 8, 2023May 4, 2023Aug 3, 2023Nov 6, 2023Mar 13, 2024May 28, 2024Aug 6, 2024Nov 4, 2024Mar 14, 2025May 12, 2025Aug 4, 2025Nov 7, 2025Mar 11, 2026May 11, 2026Aug 6, 2026Nov 6, 2026
EPS Estimate-0.04-0.36-0.31-0.30-0.36-0.40-0.39-0.38-0.37-0.22-0.34-0.72-0.38-0.34-0.31-0.71-0.32-0.36-0.42-0.73-0.65-0.74-0.50-0.78-0.72-0.65-0.75-0.92-0.66-0.57-0.21-0.71-0.42-0.34-0.36-0.22-0.27-0.27-0.24-0.09-0.16-0.15-0.10-0.29-0.26-0.25-
EPS Actual0.25-0.63-0.390.65-0.53-0.20-0.01-0.38-0.17-0.43-0.37-0.76-0.390.03-0.36-0.53-0.26-0.65-0.23-0.880.47-0.76-0.71-0.95-0.28-0.88-0.82-0.55-0.70-0.42-0.63-0.59-0.55-0.15-0.37-0.70-0.14-0.27-0.22-0.16-0.17-0.220.02-0.24-0.18-0.22-
Surprise725.00%-75.00%-25.81%316.67%-47.22%50.00%97.44%0.00%54.05%-95.45%-8.82%-5.56%-2.63%108.82%-16.13%25.35%18.75%-80.56%45.24%-20.55%172.31%-2.70%-42.00%-21.79%61.11%-35.38%-9.33%40.22%-6.06%26.32%-200.00%16.90%-30.95%55.88%-2.78%-218.18%48.15%0.00%8.33%-77.78%-6.25%-46.67%120.00%18.59%30.77%12.00%-
TimingAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap144.03M
Enterprise Value78.34M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales2.26
Price / Book3.85
EPS-0.63
Book Value0.565
Revenue (TTM)63.82M
Gross Profit (TTM)63.82M
EBITDA-46.68M
Profit Margin-102.34%
Operating Margin-340.69%
Return on Equity-94.54%
Return on Assets-11.67%
Shares Outstanding72.72M
Shares Float48.58M
Beta2.77
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 5 analystsTarget 5.33
  • Strong Buy
    1
  • Buy
    2
  • Hold
    2

Ownership Breakdown

Institutions
15.36%
Insiders
0.00%
Retail / Other
84.64%

Top Institutional Holders

  • B Group, Inc
    3.28M3.26%
  • UBS Asset Mgmt Americas Inc
    3.18M3.16%
  • Long Focus Capital Management, LLC
    2.74M2.72%
  • BlackRock Inc
    341.52K0.34%
  • Delaware Management Holdings Inc
    226.88K0.23%
  • Morgan Stanley - Brokerage Accounts
    86.78K0.09%
  • LPL Financial Corp
    84.34K0.08%
  • Susquehanna International Group, LLP
    65.94K0.07%
  • Marshall Wace Asset Management Ltd
    41.11K0.04%
  • BNP Paribas Arbitrage, SA
    41.00K0.04%
  • UBS Group AG
    29.77K0.03%
  • Delaney Dennis R
    24.00K0.02%
  • XTX Topco Ltd
    16.27K0.02%
  • Rhumbline Advisers
    15.09K0.01%

Top Fund Holders

  • UBS Lux Dgtl Hlth Eq Fd seeding P acc
    1.03M1.02%
  • iShares Biotechnology ETF
    235.70K0.23%
  • Nomura Healthcare Fund Class I
    226.88K0.23%
  • Galileo - Biotech Innovation Fund S USD
    226.07K0.22%
  • Ox Capital Dynamic Asia N USD Unhdgd Acc
    95.29K0.09%
  • Prisma Cube
    30.00K0.03%